SDMHF:OTC-Sartorius Stedim Biotech S.A (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 218

Change

0.00 (0.00)%

Market Cap

USD 19.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

-0.05 (-0.02%)

USD 128.93B
ESLOY Essilor International SA

-1.33 (-0.91%)

USD 123.63B
HOCPF HOYA Corporation

+9.72 (+9.19%)

USD 36.78B
HOCPY Hoya Corp

+1.36 (+1.20%)

USD 36.78B
CLPBY Coloplast A

+0.12 (+1.11%)

USD 30.06B
TRUMF Terumo Corporation

-1.72 (-8.77%)

USD 27.92B
CLPBF Coloplast A/S

N/A

USD 23.07B
SRTOY Sartorius Stedim Biotech S.A

+0.14 (+0.58%)

USD 21.84B
SAUHF Straumann Holding AG

+0.36 (+0.30%)

USD 17.44B
SOAGY Sartorius Aktiengesellschaft

+0.16 (+0.30%)

USD 15.21B

ETFs Containing SDMHF

LBAY Tidal ETF Trust - Leather.. 4.24 % 0.00 %

+0.03 (+1.14%)

USD 0.03B
DVLU First Trust Dorsey Wright.. 2.87 % 0.60 %

+0.42 (+1.14%)

USD 0.03B
KIE SPDR® S&P Insurance ETF 1.99 % 0.35 %

+0.15 (+1.14%)

N/A
RNDM 1.76 % 0.65 %

N/A

N/A
PAMC Pacer Lunt MidCap Multi-F.. 1.75 % 0.00 %

+0.46 (+1.14%)

USD 0.06B
XMVM Invesco S&P MidCap Value .. 1.68 % 0.39 %

+0.75 (+1.14%)

USD 0.23B
XMLV Invesco S&P MidCap Low Vo.. 1.50 % 0.25 %

+0.51 (+1.14%)

USD 0.78B
TQSM:CA TD Q U.S. Small-Mid-Cap E.. 1.49 % 0.00 %

+0.32 (+1.14%)

CAD 0.19B
HSMV First Trust Horizon Manag.. 1.48 % 0.00 %

+0.20 (+1.14%)

USD 0.02B
AFMC First Trust Active Factor.. 1.40 % 0.00 %

+0.47 (+1.14%)

USD 0.04B
SCIX 1.04 % 0.38 %

N/A

N/A
DJMC:LSE iShares EURO STOXX Mid UC.. 0.00 % 0.00 %

-4.00 (1.14%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.79% 72% C 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.79% 70% C- 67% D+
Trailing 12 Months  
Capital Gain -2.87% 57% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.87% 56% F 50% F
Trailing 5 Years  
Capital Gain -1.71% 65% D 54% F
Dividend Return 2.19% 4% F 4% F
Total Return 0.47% 63% D 49% F
Average Annual (5 Year Horizon)  
Capital Gain -6.55% 33% F 29% F
Dividend Return -6.27% 33% F 27% F
Total Return 0.28% 22% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 37.56% 62% D 61% D-
Risk Adjusted Return -16.69% 37% F 28% F
Market Capitalization 19.85B 84% B 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector